Translational data confirms activity of DCC-2618

Deciphera Pharmaceuticals has presented data that confirms the broad spectrum of activity of its pan-KIT and PDGFR inhibitor, DCC-2618, at the American Association for Cancer Research (AACR) meeting in Washington DC. Read more

4 Apr 2017 10:47 News